These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 27773395)

  • 1. Differential residual dyslipidemia/cardiovascular risk after statin treatment between Asian-Indians and western whites. Call for action.
    Athyros VG; Doumas M; Karagiannis A
    Indian Heart J; 2016; 68(5):596-598. PubMed ID: 27773395
    [No Abstract]   [Full Text] [Related]  

  • 2. "If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.
    Tenenbaum A; Fisman EZ
    Cardiovasc Diabetol; 2010 Jun; 9():24. PubMed ID: 20550659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolving Role of Non-Statin Therapy for the Management of Dyslipidemia and Cardiovascular Risk Reduction: Past, Present, and Future.
    Sisson EM; Pamulapati L; Bucheit JD; Kelly MS; Dixon DL
    Pharmacotherapy; 2018 Feb; 38(2):164-171. PubMed ID: 29266309
    [No Abstract]   [Full Text] [Related]  

  • 4. Managing the dyslipidemia of metabolic syndrome: beyond statin therapy.
    Jialal I; Smith G
    Metab Syndr Relat Disord; 2012 Jun; 10(3):159-60. PubMed ID: 22568574
    [No Abstract]   [Full Text] [Related]  

  • 5. Residual risk and high-density lipoprotein cholesterol levels: is there a relationship?
    Shah PK
    Rev Cardiovasc Med; 2011; 12(2):e55-9. PubMed ID: 21796083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Residual risk of cardiovascular complications and its reduction with a combination of lipid lowering agents].
    Soska V
    Vnitr Lek; 2011 Mar; 57(3):313-6. PubMed ID: 21495414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is lipid management effective for all stages of CKD?
    Ku E; Campese V
    Blood Purif; 2013; 35(1-3):26-30. PubMed ID: 23343543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Residual dyslipidaemia after statin treatment in France: Prevalence and risk distribution.
    Ferrières J; Bérard E; Crisan O; Bongard V
    Arch Cardiovasc Dis; 2010 May; 103(5):302-9. PubMed ID: 20619240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
    Tenenbaum A; Fisman EZ
    Cardiovasc Diabetol; 2012 Nov; 11():140. PubMed ID: 23150952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of statins in Asians.
    Liao JK
    Am J Cardiol; 2007 Feb; 99(3):410-4. PubMed ID: 17261409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dyslipidemia in special ethnic populations.
    Pu J; Romanelli R; Zhao B; Azar KM; Hastings KG; Nimbal V; Fortmann SP; Palaniappan LP
    Cardiol Clin; 2015 May; 33(2):325-33. PubMed ID: 25939303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is lipid goal one-size-fits-all: A review of evidence for recommended low-density lipoprotein treatment targets in Asian patients.
    Wang Y; Yan BP; Tomlinson B; Lee VW
    Eur J Prev Cardiol; 2019 Sep; 26(14):1496-1506. PubMed ID: 31023098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
    Wong ND; Chuang J; Zhao Y; Rosenblit PD
    J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implications of American College of Cardiology/American Heart Association (ACC/AHA) Cholesterol Guidelines on Statin Underutilization for Prevention of Cardiovascular Disease in Diabetes Mellitus Among Several US Networks of Community Health Centers.
    Akhabue E; Rittner SS; Carroll JE; Crawford PM; Dant L; Laws R; Leo MC; Puro J; Persell SD
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28673901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z
    Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacologic interactions of multidrug therapy for dyslipidemia.
    Mehta N; deGoma EM
    Curr Atheroscler Rep; 2013 Feb; 15(2):303. PubMed ID: 23299643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of dyslipidemia and cardiovascular outcomes: the journey so far--is this the end for statins?
    Zoungas S; Curtis AJ; McNeil JJ; Tonkin AM
    Clin Pharmacol Ther; 2014 Aug; 96(2):192-205. PubMed ID: 24727468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia?
    Agouridis AP; Rizos CV; Elisaf MS; Filippatos TD
    Rev Diabet Stud; 2013; 10(2-3):171-90. PubMed ID: 24380091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging therapies for residual risk.
    Mehra S; Movahed H; Movahed A
    Rev Cardiovasc Med; 2012; 13(1):e24-31. PubMed ID: 22565535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimated Cardiovascular Risk and Guideline-Concordant Primary Prevention With Statins: Retrospective Cross-Sectional Analyses of US Ambulatory Visits Using Competing Algorithms.
    Fairman KA; Romanet D; Early NK; Goodlet KJ
    J Cardiovasc Pharmacol Ther; 2020 Jan; 25(1):27-36. PubMed ID: 31353942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.